Results from a meta-analysis suggest patients with resectable dMMR/MSI-H gastric cancer can forgo perioperative chemotherapy.

Cancer drugs conferring low or no therapeutic benefits accounted for $6.7 billion in post-rebate Medicare spending in 2022.

Surufatinib did not provide an OS benefit over placebo, but there was a high rate of crossover from the placebo group to the surufatinib group.

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic MSI-H/dMMR colorectal cancer.

The US Senate has confirmed the appointment of Mehmet Oz, MD, to head the Centers for Medicare & Medicaid Services.

The Trump administration is attempting to slash NIH funding, terminate research grants, and reduce the agency’s workforce.

Some recent cuts at government health agencies may be reversed, including a key program that tracks lead exposure in children, the HHS secretary said last week.

Patients who develop secondary rectal cancer after receiving radiotherapy for prostate cancer have worse survival outcomes than patients with primary rectal cancer, and several factors may be driving ...

Ensuring timely completion of post-approval studies and enforcing appropriate regulatory actions based on negative trial results is necessary to minimize patient exposure to ineffective and ...

Combination treatment with a PARP inhibitor and an anti-angiogenic agent did not improve PFS when compared to chemotherapy or a PARP inhibitor alone.

Artificial intelligence (AI) can accurately suggest appropriate adjuvant treatment for patients with early breast cancer, according to research published in JCO Clinical Cancer Informatics.

The rising trajectory in the inability to pay for health care is a disturbing trend that is likely to continue and even accelerate,” said Tim Lash.